Olema Oncology announced a clinical trial collaboration with Bayer to evaluate OP-3136, a KAT6 inhibitor, in combination with darolutamide in approximately 36 patients with metastatic castration-resistant prostate cancer. The Phase 1b/2 study is expected to initiate in H2 2026 and represents the first clinical collaboration for OP-3136. Olema will lead the study while maintaining full global commercial rights to OP-3136, with clinical data and inventions jointly owned.

Olema Oncology announced positive Phase 1 clinical data for OP-3136, a KAT6 inhibitor, showing no dose-limiting toxicities, manageable adverse events, and tumor shrinkage in over two-thirds of evaluable patients across multiple solid tumor types. The company plans to continue development as monotherapy and in combination with other agents including palazestrant.

The ESR1-mutated metastatic breast cancer market is projected to grow at 9.6% CAGR through 2036, driven by rising prevalence of endocrine-resistant HR-positive/HER2-negative breast cancer and adoption of precision oncology. Novel oral SERDs and targeted agents from major pharmaceutical companies are reshaping the treatment landscape. The market was valued at USD 1.5 billion in 2025, with the US representing the largest market share. Recent FDA approvals include VEPPANU (vepdegestrant), the first PROTAC therapy, while several emerging therapies are in clinical development.

Olema Oncology reported strong execution in 2025 with advanced enrollment in pivotal Phase 3 trials for palazestrant (OPERA-01 and OPERA-02) in ER+/HER2- metastatic breast cancer. The company initiated a Phase 1b/2 study with Pfizer's atirmociclib and expects top-line OPERA-01 data in fall 2026. Olema raised $218.5 million in gross proceeds from a public offering, ending 2025 with $505.4 million in cash. The company is preparing for potential commercial launch in late 2027.

The DJS Law Group is investigating Olema Pharmaceuticals (NASDAQ: OLMA) for potential securities law violations, alleging the company issued misleading statements or failed to disclose material information. The investigation was triggered by an Investor's Business Daily report indicating that a failed Roche trial for an oral breast cancer medication raises concerns about Olema's competing medication. Following the news, Olema's stock fell more than 19.6% in morning trading on March 9, 2026.

Olema Pharmaceuticals board member Ian T. Clark sold approximately $7.9 million worth of shares (264,800 shares) on December 19, representing a complete exit from his direct equity holdings. The sale followed a 326.5% one-year stock surge driven by recent analyst upgrades and encouraging clinical trial updates. The company, focused on breast cancer therapies, has strengthened its balance sheet with a $218.5 million equity raise and maintains $329 million in cash runway into 2028.

Olema Pharmaceuticals plans to launch a public offering of common stock or pre-funded warrants, with TD Cowen acting as book-running manager. The offering is subject to market conditions and regulatory approvals.

Martin Shkreli announced shorting Olema Pharmaceuticals stock, criticizing the company's valuation in the SERD drug market. Despite Shkreli's stance, Olema's stock surged over 140% after positive phase 3 results from Roche's breast cancer study, with analysts raising price targets.

Olema Oncology presented promising Phase 1b/2 trial results showing palazestrant combined with ribociclib demonstrated encouraging progression-free survival and tolerability in ER+/HER2- metastatic breast cancer patients, supporting ongoing Phase 3 clinical trials.

Olema Oncology announced the selection of a 90 mg once-daily dose of palazestrant for its Phase 3 OPERA-01 monotherapy trial and OPERA-02 combination trial with ribociclib. The company will present a trial-in-progress poster for OPERA-01 at the ASCO 2025 Annual Meeting.

The metastatic HR+/HER2- breast cancer market is expected to grow due to the launch of several novel emerging therapies, which are anticipated to change the treatment landscape and improve survival outcomes for this patient population.

Olema Oncology presented preclinical data demonstrating the anti-tumor activity of OP-3136, a KAT6 inhibitor, in prostate, ovarian, and non-small cell lung cancer models. The data showed potent tumor growth inhibition and sustained tumor regression in various cancer models, supporting the potential utility of OP-3136 beyond breast cancer.